EcoDrugPlus

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSACIG00000002462
Gene Symbol: IRAK4
1 Cross references
202 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSACIG00000015438
Gene Symbol: IDH1
1 Cross references
227 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSACIG00000007114
Gene Symbol: IDH1
1 Cross references
232 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSACIG00000021021
Gene Symbol: IDH2
1 Cross references
204 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSACIG00000023731
Gene Symbol: IDH2
1 Cross references
196 Possible Orthologues:

Kelch-Like Ech-Associated Protein 1b

Ensembl ID : ENSACIG00000003284
Gene Symbol: KEAP1B
1 Cross references
189 Possible Orthologues:

Kinase Insert Domain Receptor (A Type Iii Receptor Tyrosine Kinase)

Ensembl ID : ENSACIG00000023323
Gene Symbol: KDR
1 Cross references
198 Possible Orthologues:

Kinesin Family Member 11

Ensembl ID : ENSACIG00000012045
Gene Symbol: KIF11
1 Cross references
202 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSACIG00000014998
Gene Symbol: KIF5B
2 Cross references
243 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSACIG00000001516
Gene Symbol: KIF5B
2 Cross references
245 Possible Orthologues:

Lectin, Galactoside Binding Soluble 3a

Ensembl ID : ENSACIG00000011857
Gene Symbol: LGALS3A
1 Cross references
220 Possible Orthologues:

Leukotriene A4 Hydrolase

Ensembl ID : ENSACIG00000005748
Gene Symbol: LTA4H
1 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).